Met/HGF receptor modulates bcl-w expression and inhibits apoptosis in human colorectal cancers by Kitamura, S et al.
The c-met oncogene encodes a cell-surface tyrosine kinase
receptor for hepatocyte growth factor (HGF)/scatter factor
(Bottaro et al, 1991; Naldini et al, 1991), a potent mitogen for
epithelial cells which also promotes cell movement. The HGF-Met
signaling pathway has been shown to be involved in tumour
development and progression. The coexpession of HGF and Met
molecules, which generates an autocrine stimulatory loop, is
tumourigenic in NIH3T3 cells (Rong et al, 1992). In addition to
tumorigenicity, deregulated HGF-Met signalling has also been
shown to enhance in vitro invasiveness (Bhargava et al, 1992;
Giordano et al, 1993; Rong et al, 1994; Rosen et al, 1994) and in
vivo metastatic potential (Rong et al, 1994; Rosen et al, 1994) of
various cell types. The results from several recent studies suggest
that the HGF-Met system modulates the process of apoptosis. For
example, HGF has been shown to protect canine renal tubular
epithelial cells against apoptosis induced by the detachment of
cells from their substrate (Frisch and Francis, 1994). An infusion
of HGF inhibited apoptosis of rat hepatic ductal cells after the
administration of the hepatocarcinogen 2-acetylaminofluorene
(Nagy et al, 1996). Furthermore, transgenic expression in the liver
of truncated Met, a constitutively active oncogenic form of c-met,
blocked staurosporine-induced apoptosis of hepatocytes (Amicine
et al, 1997).
It has been reported that the c-met gene is over-expressed in a
high percentage of colorectal adenomas and carcinomas (Liu et al,
1992; Di Renzo et al, 1995; Umeki et al, 1999). However, the issue
of whether Met expression in colorectal tumours is involved in
resistance to apoptosis is presently unclear. The purpose of this
study was to investigate the role of Met expression in the modula-
tion of apoptosis in colorectal tumours. In the present study, the
gene expressions of c-met and the anti-apoptotic bcl-2 family,
including  bcl-2,  bcl-xL and  bcl-w, were analysed in human
colorectal adenomas and adenocarcinomas by means of a quantita-
tive polymerase chain reaction combined with reverse transcrip-
tion (RT-PCR), a technique which we have already employed in
other studies (Kondo et al, 1995; 1996). An apparent correlation
between c-met and bcl-w mRNA levels in colorectal tumours was
found. Furthermore, we showed that the inhibition of Met produc-
tion by c-met antisense promotes apoptosis induced by serum
deprivation and inhibits the gene expression of bcl-w but not bcl-2
or bcl-xL in LoVo human colon cancer cells.
MATERIALS AND METHODS
Subjects
The study involved five control subjects (three males and two
females; age range, 36–58 years) with no colorectal lesions as
evidenced by endoscopy, 12 patients with colorectal adenoma
(seven males and five females; age range, 46–77 years) and 11
patients with colorectal carcinoma (seven males and four females;
age range, 35–71 years). Informed consent was obtained from
each subject. Four tissue specimens were obtained from normal
control mucosa, adenomas, carcinomas, and surrounding non-
neoplastic mucosa in the case of patients with an adenoma or
carcinoma for histologic evaluation and extraction of RNA.
Formalin-fixed, paraffin-embedded tumours were stained with
haematoxylin and eosin and classified histologically by expert
pathologists as well-differentiated adenocarcinoma (n = 10),
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doi: 10.1054/ bjoc.2000.1301, available online at http://www.idealibrary.com on moderately differentiated adenocarcinoma (n = 1), adenoma
without severe dysplasia (n = 8), or adenoma with severe dysplasia
(n = 4). This study was approved by ethical committee.
Cells and cell culture
Human colon cancer LoVo cells were cultured in Ham’s F-12 medium
(Gibco BRL, Grand Island, NY, USA) supplemented with 10% heat-
inactivated fetal calf serum (Whittaker Bioproducts, Walkersville,
MD, USA), 100 units ml–1 penicillin, and 100 mg ml–1 streptomycin in
a water-saturated atmosphere containing 5% CO2 at 37° C.
RNA extraction
Total RNA was extracted from tissue specimens (three of the
biopsy specimens) and LoVo cells using the guanidinium thio-
cyanate/acid phenol method. As an internal standard, total RNA
was extracted from mouse and rat colon.
Oligonucleotides used for amplification
In order to amplify c-met, bcl-w, bcl-2 and bcl-xL mRNA in tissue
specimens and LoVo cells by nested PCR, two pairs of primers
were synthesized. The primer sequences were as follows: (a) 5′ -
GATCTGGGCAGTGAATTAGT-3′ and 5′ -TCTT TCATGAT-
GATTCCCCTC-3′ for the first-step c-met amplification (Park et
al, 1987; Chan et al, 1988); (b) 5′ -GTAAGTGCCCGAAGTG-
TAAG-3′ and 5′ -CAAGGATTTCACAGCACAGT-3′ for the
second-step c-met amplification; (c) 5′ -TATAAGCTGAGGCA-
GAAGGG-3′ and 5′ -TCAGCACTGTCCTCACTGAT-3′ for the
first-step bcl-w amplification (Gibson et al, 1996); (d) 5′ -TTAT-
GTCTGTGGAGCTGG CC-3′ and 5′ -TCTCCAGGTAGGCCAC-
CATC-3′ for the second-step bcl-w amplification; (e)
5′ -CAGCTGCACCTGACGCCCTT-3′ (which is also used for the
second-step bcl-2 amplification) and 5′ -GCCTCCGTTATCCTG-
GATCC-3′ for the first-step bcl-2 amplification (Cleary et al,
1986; Negrini et al, 1987); (f) 5′ -CAGCT GCACCTGACGC-
CCTT-3′ and 5′ -GCCGGTTCAGGTACTCAGTC-3′ for the
second-step  bcl-2 amplification; (g) 5′ -AAGGATACAGCTG-
GAGTCAG-3′ and 5′ -ATCCGACTCACCAATACCTG-3′ for the
first-step bcl-xL amplification (Boise et al, 1993; González-García
et al, 1994); (h) 5′ -ATCAATGGCAACCCATCCTG-3′ and 5′ -
CTACGCTTTCCACGCACAGT-3′ for the second-step bcl-xL
amplification. For the amplification of 28S rRNA, a pair of PCR
primers was synthesized. The sequences were 5′ -CCATGT-
GAACAGCAGTTGAA-3′ and 5′ -CCCTGCCCTTCACAAA-
GAAA-3′ (Hadjiolov et al, 1984; González et al, 1985). Although
both the human and internal standard cDNAs originating from c-
met mRNA, bcl-w mRNA, bcl-2 mRNA, bcl-xL mRNA, or 28S
rRNA are amplified by the same primers, only the human DNA
fragments amplified with these primers contained an, Mva I (c-
met), Dpn II (bcl-w), Ban II (bcl-2), Ava I (bcl-xL), or Eae I (28S
rRNA) restriction endonuclease site.
RT-PCR
The conversion of RNA to cDNA was carried out in a final volume
of 5 µ l containing 1 µ g or less human and mouse RNA mixture of
different proportion in the reaction solution of 50 mM Tris-HCl,
pH 8.3, 50 mM KCl, 10 mM MgCl2, 3 mM dithiothreitol, 10 µ M
random primer (Takara Shuzo, Kyoto, Japan), 1 mM each dNTPs,
6 units RNase inhibitor (Pharmacia LKB Biotechnology, Tokyo,
Japan), and 1 unit RAV-2 reverse transcriptase (Takara Shuzo).
The c-met, bcl-w, bcl-2, and bcl-xL cDNAs (0.5 µ l of the reverse
transcription product) were amplified by nested PCR with two
pairs of primers in PCR buffer, containing 10 mM Tris-HCl, pH
8.3, 50 mM KCl, 1.5 mM MgCl2, 0.001% (w/v) gelatin, 400 µ M
of each dNTP, 1 µ M each of the first-step or second-step 5′ and 3′
primers, and 0.25 units of Thermus aquaticus DNA polymerase
(Taq polymerase) (Perkin-Elmer Cetus, Norwalk, CT, USA). Each
amplification profile involved denaturation at 94° C for 1 min,
primer annealing at 55° C for 2 min, and extension at 72° C for 3
min. The profile was repeated for 30 cycles. After the second-step
PCR amplification, 1 µ l from each sample was added to 20 µ l of
fresh PCR buffer containing the second-step 5′ and 3′ primers, and
subjected to one additional cycle to prevent heterodimeric DNA
formation between the human and mouse PCR products (Kondo et
al, 1995). For the determination of the 28S rRNA concentration,
rat 28S rRNA was used for the internal standard and the cDNA
from human and rat 28S rRNA was amplified for 30 cycles and
one additional cycle as described previously (Kondo et al, 1995).
Quantitative analysis
After the amplification step was completed, the DNA fragments
corresponding to the c-met mRNA, bcl-w mRNA, bcl-2 mRNA,
bcl-xL mRNA and 28S rRNA were digested with Mva I (New
England Biolabs, Beverly, MA, USA), Dpn II (Takara Shuzo), Ban
II (Takara Shuzo), Ava I (New England Biolabs,) and Eae I
(Takara Shuzo), respectively. The digested samples were then
injected directly into a high-performance liquid chromatography
(HPLC) system with a UV-spectrophotometric detector (Model
SPD-6A, Shimadzu, Kyoto, Japan) operated at 260 nm. The
analytical column was a TSK gel DEAE-NPR (Tosoh, Tokyo,
Japan). The digested DNA fragments were chromatographed
under a 20 min linear gradient of NaCl from 0.4–0.6 M prepared in
20 mM Tris-HCl, pH 9.0, at a flow rate of 1.0 ml min–1. The HPLC
elution profile revealed the baseline separation of three DNA frag-
ments. The resulting fragments were identified as two human frag-
ments (c-met: 145 base pairs (bp) and 242 bp: bcl-w: 109 bp and
208 bp; bcl-2: 55 bp and 144 bp; bcl-xL: 80 bp and 236 bp; 28S:93
bp and 148 bp) and an internal standard fragment (c-met: 387 bp;
bcl-w: 317 bp; bcl-2: 199 bp; bcl-xL: 316 bp; 28S: 241 bp). For the
determination of the c-met mRNA, bcl-w mRNA, bcl-2 mRNA,
bcl-xL mRNA and 28S rRNA levels, the peak-height ratio of the
242 bp to the 387 bp fragment, the 208 bp to the 317 bp fragment,
the 144 bp to the 199 bp fragment, the 236 bp to the 316 bp frag-
ment and the 148 bp to the 241 bp fragment were measured,
respectively. The coefficient of variation of this assay was 8.5%
for c-met mRNA, 9.4% for bcl-w mRNA, 9.2% for bcl-2 mRNA,
7.2% for bcl-xL mRNA and 9.0% for 28S rRNA. The c-met, bcl-w,
bcl-2 and bcl-xL mRNA levels were expressed as a relative c-met
mRNA/28S rRNA ratio, a relative bcl-w mRNA/28S rRNA ratio, a
relative  bcl-2 mRNA/28S rRNA ratio, and a relative bcl-xL
mRNA/28S rRNA ratio, respectively.
Antisense oligonucleotides
HPLC-purified 20-mer c-met antisense oligonucleotides and
nonsense (a scramble version) control oligonucleotides were
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cleotides straddled the predicted translation-initiation site of
human c-met mRNA. The sequences used were 5′ -
ACAGCGGGGGCCTTCATTAT-3′ (c-met-antisense) and 5′ -
TCGGCTACAAGCTACGGTTG-3′ (c-met-nonsense).
Western blot analysis
Cells were washed in PBS and lysed in lysis buffer containing 
20 mM Tris (pH 8.0), 137 mM NaCl, 10% glycerol, 1% Nonidet
P-40, 10 mM EDTA, 100 mM NaF, 1 mM PMSF, 0.25 TIU ml–1 of
aprotinin, and 10 µ g ml–1 of leupeptin. Aliquots containing 30 µ g
of total protein were size-fractionated by sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (5–20% gradient
gels). Immunoblot analysis was performed as described previously
using a rabbit anti-Met antibody (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) (Kitamura et al, 1999). Protein concentrations of
the homogenates were determined using a bicinchoninic acid
protein assay reagent (Pierce, Rockford, IL, USA).
Number of viable cells and cell viabilities
LoVo cells were seeded at 5 × 104 cells per 60 mm dish and
cultured in Ham’s F-12 medium supplemented with 10% heat-
inactivated foetal calf serum. After preincubation with 10 µ M c-
met-antisense or c-met-nonsense oligonucleotides for 4 days,
medium was removed and replaced with serum-deprived medium
containing 10 µ M c-met-antisense or c-met-nonsense oligo-
nucleotides. The serum-deprived medium containing oligo-
nucleotides was not changed until measurement of cell viabilities.
The number of viable cells was determined by haemocytometry
using trypan blue exclusion.
Measurement of apoptosis by flow cytometry
DNA degradation was assessed by measuring the DNA content of
individual cells by flow cytometry. In preparation for flow cytom-
etry, cells were collected after brief trypsinization, washed with
PBS, and fixed in 70% cold ethanol. Samples were then treated
with RNase, stained with 10 µ g ml–1 propidium iodine, and
analysed using a Becton Dickinson FACScan. Cell-cycle distribu-
tions were quantified using Cell-quest software.
Statistical analysis
Statistical analysis was made using Wilcoxon matched-pairs
signed-rank test or Mann – Whitney U test. A level of P < 0.05
was accepted as statistically significant. For the measurements of
the levels of c-met mRNA, bcl-w mRNA, bcl-2 mRNA, bcl-xL
mRNA and 28S rRNA, each data-point represents the mean of
three measurements.
RESULTS
Gene expression of c-met, bcl-w, bcl-2 and bcl-xL in
human colorectal adenomas and carcinomas
In seven of 12 (58%) adenomas and seven of 11 (64%) carci-
nomas, the c-met gene was found to be overexpressed (Figure 1),
when overexpression is defined as an increase of greater than 
two-fold over the expression in adjacent normal tissue. The bcl-w,
bcl-2 and bcl-xL genes were overexpressed in nine (75%), five
(42%) and six (50%) of 12 adenomas and in five (45%), two
(18%) and seven (64%) of 11 carcinomas, respectively. The levels
of  bcl-w mRNA in tumours with c-met-overexpression were
apparently higher compared with the levels in tumours without c-
met-overexpression (Figure 2). A significant correlation (correla-
tion coefficient (r) = 0.754, P < 0.0001) was observed between the
bcl-w mRNA levels and c-met mRNA levels (data not shown).
The levels of bcl-2 or bcl-xL mRNA were not correlated with the
gene expression of c-met in colorectal adenomas and carcinomas.
Evaluation of c-met protein levels by Western blotting
The c-Met protein in LoVo cells was detected as a single polypep-
tide with a molecular weight of 190 kDa, a finding consistent with
previous reports that LoVo cells express constitutively activated
Met protein which is uncleaved because of defective post-transla-
tional processing (Mondino et al, 1991). When added to cultures
of LoVo cells for 4 days, c-met-antisense produced concentration-
dependent reductions in the steady state levels of Met protein
(Figure 3). In contrast, the Met protein level of 10 µ M c-met-
nonsense-treated cells was similar to that of untreated cells.
Effect of antisense oligonucleotides to c-met on
apoptosis induced by serum deprivation
After preincubation of LoVo cells with 10 µ M c-met-antisense or
c-met-nonsense oligonucleotides for 4 days, the serum was
removed from the medium. Pretreatment with antisense oligonu-
cleotides rapidly decreased the number of viable cells after serum
deprivation in a time-dependent manner (Figure 4). Nonsense-
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Figure 1 Gene expression of c-met (A), bcl-w (B), bcl-2 (C) and bcl-xL (D)
in colorectal adenomas and carcinomas. Tissue specimens were obtained
from normal control mucosa, adenomas, carcinomas, and the surrounding
non-neoplastic mucosa in patients with an adenoma or carcinoma. The levels
of c-met mRNA, bcl-w mRNA, bcl-2 mRNA and bcl- xL mRNA were
determined using a quantitative polymerase chain reaction combined with
reverse transcription. N and T indicate the surrounding non-neoplastic
mucosa and tumour, respectively. Each pair is linked by a solid line. NS; not
statistically significanttreated cells survived for more than 6 days after serum deprivation.
In order to determine if the decrease in the number of viable cells
after serum deprivation could be attributed to apoptosis, the
number of apoptotic cells was measured by flow cytometry.
Fragmented DNA contained in apoptotic cells resulted in an
unequivocal hypodiploid DNA peak that was distinguishable from
the diploid DNA peak seen in LoVo cells after serum deprivation
(Figure 5A). The increase in apoptotic cells after serum depriva-
tion was more prominent in c-met-antisense-pretreated cells than
in the control or c-met-nonsense-pretreated cells (Figure 5B).
Effect of antisense oligonucleotides to c-met on gene
expression of bcl-w, bcl-2 and bcl-xL
After incubation of LoVo cells with 10 µ M c-met-antisense or c-
met-nonsense oligonucleotides for 4 days, expression levels of bcl-
w,  bcl-2 and bcl-xL mRNAs were determined by competitive
RT-PCR method. In the case of the c-met-antisense treated cells,
the bcl-w mRNA level was decreased when compared to either
untreated or c-met-nonsense-treated cells (Figure 6). Gene expres-
sion of bcl-2 or bcl-xL of LoVo cells was not affected by treatment
with c-met-antisense or c-met- nonsense oligonucleotides.
DISCUSSION
The c-met oncogene encodes the receptor for HGF, a potent
mitogen for epithelial cells that also promotes cell motility and
invasiveness. It has recently been suggested that HGF protects
Met modulates apoptosis in colorectal cancer 671
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Figure 2 Correlation between the gene expression of c-met and the anti-
apoptotic bcl-2 family (A = bcl-w; B = bcl-2; C = bcl-xL) in colorectal
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Figure 3 Western blot analysis of Met protein. Cells were lysed after
incubation for 4 days with various concentrations of c-met-antisense or c-
met-nonsense oligonucleotides. Total protein (30 µ g) from each sample was
loaded on 5–20% gradient SDS-polyacrylamide gels. The samples are:
control LoVo cells (lane 1), 10 µ M c-met-nonsense (lane 2), 1.25 µ M c-met-
antisense (lane 3), 2.5 µ M c-met-antisense (lane 4), 5 µ M c-met-antisense
(lane 5), and 10 µ M c-met-antisense-treated cells (lane 6)
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cells after serum deprivation. Cells were seeded at 5 × 104 cells per 60 mm
dish. After pre-incubation for 4 days with 10 µ M c-met-antisense (open circle)
or c-met-nonsense (open triangle) oligonucleotides, serum was removed
from the medium. Several cultures received no oligonucleotides (closed
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(A) DNA fluorescence histogram of propidium iodide-stained cells after
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epithelial cells against apoptosis induced by various stimuli
(Frisch and Francis, 1994; Fan et al, 1998). Previous studies have
shown that the c-met gene is overexpressed in colorectal adenomas
and carcinomas (Liu et al, 1992; Di Renzo et al, 1995; Umeki et al,
1999). In the present study, we investigated the role of c-met
expression in colorectal tumours in the modulation of apoptosis.
The relationship between the mRNA expression level of c-met and
those of the anti-apoptotic bcl-2 family including bcl-w, bcl-2, bcl-
xL was examined in colorectal adenomas and carcinomas. The
overexpression of the c-met gene was detectable in more than 50%
of the lesions at both stages of adenomas and carcinomas. Our
observations are in agreement with previous reports (Liu et al,
1992; Di Renzo et al, 1995). Up-regulation of the bcl-xL gene was
also observed in adenomas and carcinomas. In contrast to bcl-xL
gene expression, the gene expression of bcl-2 seemed to decline
during the progression of adenomas to carcinomas. In some
colorectal carcinomas, the expression of bcl-2 gene was decreased
compared with that in adjacent normal tissues. These results are in
agreement with earlier immunohistochemical study in which Bcl-2
and Bcl-xL protein expression was examined (Krajewska et al,
1996). In this study, we demonstrated, for the first time, the over-
expression of the bcl-w gene in many colorectal adenomas and
carcinomas. Furthermore, the expression level of the bcl-w gene
was correlated with the c-met expression level.
In order to clarify the role of Met expression on cell survival and
gene expression of the anti-apoptotic bcl-2-related gene, we
treated LoVo human colon cancer cells with c-met-antisense
oligonucleotides. In LoVo cells, although no mutations were
present in the Met-coding region, the tyrosine kinase encoded by
the c-met proto-oncogene is constitutively activated via a defective
post-translational processing of the precursor protein (Mondino et
al, 1991). c-met-antisense oligonucleotides effectively inhibited
Met protein production and increased the level of apoptotic cell
death after serum deprivation, suggesting that Met expression in
colon cancer cells plays an important role in preventing apoptosis.
Furthermore, as shown in Figure 6, the inhibition of Met produc-
tion resulted in a decrease in gene expression of bcl-w but not bcl-
2 or bcl-xL in LoVo cells.
bcl-w has been cloned as a bcl-2-related gene and has been
shown to be expressed in many tissues, especially the colon
(Gibson et al, 1996). It has been shown that the enforced expres-
sion of bcl-w enhances survival of several cell types exposed to a
variety of cytotoxic agents. High levels of Bcl-w enables a
myeloid cell line to resist apoptosis induced by IL-3 withdrawal or
γ -irradiation and a T hybridoma cell line is rendered refractory to
γ -irradiation and dexamathasone (Gibson et al, 1996). These facts,
along with our results that the decrease in Met protein content
inhibited  bcl-w expression and resulted in increased cell death
induced by serum deprivation, suggest that Met enhances cell
survival through the modulation of Bcl-w expression.
In a recent study using MDA-MB-453 human breast cancer
cells, it has been reported that pretreatment of MDA-MB-453 cells
with HGF inhibited the adriamycin-induced decrease in the levels
of Bcl-xL (Fan et al, 1998), suggesting that Bcl-xL may have a role
in HGF-mediated cell survival in some cancer cells. However, in
colorectal tumours, no relationship between c-met and bcl-xL gene
expression was observed. Furthermore, the inhibition of Met
protein production by c-met-antisense had no effect on the expres-
sion level of bcl-xL gene.
In conclusion, we demonstrated that the expression of c-met
gene is up-regulated and correlated with bcl-w expression in
human colorectal adenomas and carcinomas. The inhibition of Met
protein expression resulted in a decrease in bcl-w gene expression
and an increase in apoptotic cell death induced by serum depriva-
tion in LoVo human colon cancer cells. These observations suggest
that Met expression plays a role in the protection of cells against
apoptosis by targeting Bcl-w in colorectal tumours.
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